Radiotherapy With a 12-Gene Expression Assay for Ductal Carcinoma In Situ

Among women with ductal carcinoma in situ (DCIS), can DCIS score (DS) profiling allow selective radiotherapy use after breast-saving surgery while maintaining low ipsilateral in-breast recurrence rates?In this single-arm clinical trial of 339 women with DCIS, patients underwent breast magnetic resonance imaging and surgery, and of those who underwent wide local excision (171 [50%]), 159 (93%) accepted omission or receipt of radiotherapy based on a DS of less than 39 or 40 or greater. The 5-year ipsilateral in-breast event rate was approximately 1% annually for the low and high-intermediate DS groups.The study findings suggest that DS-based selective radiotherapy use is acceptable for patients with DCIS, allowing half the population to avoid radiotherapy while maintaining a low risk of in-breast events for all.

Corresponding Author: Seema A. Khan, MD, Feinberg School of Medicine of Northwestern University, 303 E Superior St, Lurie Research 4-111, Chicago, IL 60611 (s-khan2@northwestern.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.